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Abstract
A 31-year-old male presented with a complaint of chronic pruritus with diffuse urticarial
wheals for the past seven months. He underwent extensive workup and was found to have
positive Helicobacter pylori (H. pylori) stool antigen test. He was treated with bismuth
subsalicylate, metronidazole, tetracycline, and omeprazole for two weeks. Pruritus and
urticarial wheals disappeared in four weeks after therapy was started.
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Introduction
Urticaria is a common skin disease characterized by widespread and transient wheals. It is
classified as acute or chronic. Acute urticaria is defined as periodic outbreaks of urticarial
lesions that resolve within six weeks, and chronic urticaria (CU) persists greater than six weeks
[1]. The causes of CU are numerous; however, in at least 80%-90% of the patients, the etiology
is undetermined [2-3]. The infection by Helicobacter pylori (H. pylori) has been the subject of
investigation as a possible etiologic factor for CU in the last few years. H.pylori infection plays a
role in the development of peptic ulcer disease, chronic active gastritis, and low-grade gastric
mucosa-associated lymphoid tissue lymphoma and gastric malignancy [4-5]. We present an
unusual case of CU in an adult patient with H. pylori infection and regression of chronic
urticarial illness after treatment of H. pylori with bismuth-based quadruple therapy.
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A 31-year-old male with a past medical history of mild intermittent asthma presented with a
seven-month history of chronic pruritus with diffuse urticarial wheals (Figure 1).
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FIGURE 1: Urticarial wheals on the back

Allergy history for food, environment, and drugs was unremarkable. He underwent an extensive
workup including complete blood count, basic metabolic panel, human immunodeficiency virus
(HIV) testing, thyroid stimulating hormone, thyroid peroxidase antibodies, comprehensive
stool panel, serum immunoglobulin E (IgE) level, and chest X-ray; all were unrevealing. He was
initially treated empirically with cetirizine 5 mg daily without significant improvement. The
cetirizine dose was subsequently increased to 10 mg with only minimal improvement.
Ranitidine 150 mg twice daily was added but without much relief. A few weeks later, he
complained of new onset of epigastric pain and was subsequently tested for H. pylori by stool
antigen which resulted as positive. He was treated with bismuth subsalicylate, metronidazole,
tetracycline, and omeprazole for two weeks. Pruritus and urticarial wheals disappeared four
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weeks after therapy was started (Figure 2).

FIGURE 2: Disappearance of urticarial wheals after treatment

Repeat stool H. pylori was performed eight weeks after completing antibiotics and off
omeprazole and confirmed eradication. The patient has had no recurrence of urticaria following
treatment.

Discussion
CU is defined by the presence of urticaria, angioedema, or both for six weeks or longer. The
clinical manifestations of CU are typically limited to the skin, but sometimes systemic
symptoms are seen [6-7]. CU is associated with various autoimmune disorders such as thyroid
disorders, celiac disease, Sjogren syndrome, systemic lupus erythematosus, and type 1 diabetes
mellitus. First line treatment of CU is the H1 anti-histamines, and as the second line,
corticosteroids, leukotriene antagonists, H2 anti-histamines, immunosuppressants,
monoclonal antibodies, and intravenous human immunoglobulin [8-9].
H. pylori lives in the stomach and is a leading cause of peptic ulcer disease. H. pylori has also
been linked to a variety of conditions which can affect the skin such as CU, rosacea, psoriasis,
Henoch-Schönlein purpura, Sjögren syndrome, systemic sclerosis, generalized pruritus (itch),
atopic dermatitis, and aphthous ulceration [10-11].
Multiple studies have shown an association between CU and H. pylori infection. It is thought
that H. pylori increases the permeability of the stomach lining, therefore, increasing the
exposure to allergens in the gastrointestinal tract. Also, the immune response to H. pylori yields
antibodies that may stimulate the release of histamine in the skin [12]. IgE-containing cells in
the gastrointestinal tract seem to be the culprit, but there is limited proof for H. pylori-specific
IgE. Thus, the likelihood that patients with urticaria develop specific IgE against H. pylori is an
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appealing pathogenic explanation that likely has not been confirmed yet [10].
Shakouru et al. [13] evaluated 19 studies, 17 observational, and two double-blinded,
randomized, controlled clinical trials, and observed that 10 of these studies showed a
beneficial impact of H. pylori eradication in the resolution of the symptoms of CU.
Endoscopic and non-endoscopic methods can establish the diagnosis of H. pylori infection. The
non-endoscopic, less invasive techniques, include serologic testing, labeled urea breath test,
and the monoclonal antibody-based H. pylori stool antigen test. The endoscopic tests,
performed on gastric biopsy specimens obtained during upper endoscopy, are the rapid urease
test, histopathology, and culture [14].
Choosing the initial regimen to treat H. pylori should be guided by the presence of risk factors
for regional antibiotic resistance patterns and eradication rates. H. pylori should be treated for
14 days. Risk factors for macrolide resistance include prior exposure to macrolide therapy for
any reason and high local clarithromycin resistance rates (≥ 15%) or eradication rates with
clarithromycin-based triple treatment ≤ 85%. Initial treatment options include quadruple
bismuth therapy containing proton pump inhibitor (PPI), bismuth, metronidazole, and
tetracycline (PBMT), and concomitant non-bismuth quadruple treatment comprising PPI,
amoxicillin, metronidazole, and clarithromycin (PAMC). Patients without risk factors for
macrolide resistance should be treated with triple therapy containing clarithromycin,
amoxicillin, and PPI (CAP) [15-17]. Amoxicillin can be substituted with metronidazole only in
penicillin-allergic individuals [16-18]. Levofloxacin-based triple therapy containing
levofloaxacin, amoxillin and PPI (LAP) and sequential non-bismuth quadruple therapy (PPI,
amoxicillin followed by PPI, metronidazole, and clarithromycin) shouldn’t be used for first-line
treatment [16].
Approximately 20% of patients fail an initial attempt at H. pylori eradication. In patients with
persistent H. pylori infection, antibiotic therapy should be guided by the patient’s initial
treatment regimen, the use of other antibiotics, and the presence of relevant antibiotic
allergies. Antibiotics included in the initial regimen should generally be avoided when
prescribing a subsequent regimen. PBMT and LAP can be used in patients with no previous
metronidazole exposure. If levofloxacin therapy fails, then PBMT is the next option even if
previously exposed to metronidazole. The use of rifabutin-containing regimens (rifabutin, PPI,
amoxicillin) should be used in patients who have failed to respond to at least three prior
options. There is insufficient data to support non-bismuth quadruple therapy and PAMC for
rescue therapy.
Eradication should be confirmed in all patients treated for H. pylori because of increasing
antibiotic resistance [15,18]. Confirmation of elimination can be established with a urea breath
test, stool antigen testing, or endoscopy-based testing. Tests to confirm eradication should be
performed at least four weeks after completion of antibiotic treatment [15]. PPIs should be held
for one to two weeks before testing to reduce false-negative results. Serologic testing should
not be performed to confirm eradication as patients may continue to have circulating
antibodies even after eradication.

Conclusions
CU and dyspepsia are associated with H. pylori and its presence can be tested for by using an
affordable, noninvasive, sensitive and specific test such as H. pylori stool antigen. H. pylori
should be treated for 14 days with appropriate therapy and eradication should be confirmed.
The case demonstrates that H. pylori should be included in the diagnostic workup of chronic
urticaria, especially in patients without response to habitual treatment for chronic urticaria or
those with concurrent gastrointestinal symptoms.
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Appendices
This article has been published as a poster and can be found on the following website https://www.eventscribe.com/2018/ACG/ajaxcalls/PosterInfo.asp?
efp=RFNSWFFHSFY2NDI0&PosterID=160190
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